← Issue №10/ week of Sep 6, 2026/Nutrition

Serum-based biomarker development for dietary macronutrient densities and their association with breast and colorectal cancer risk in a cohort of postmenopausal females.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Nutrition prospective cohort · n=758 · Sep 1, 2026 · Am J Clin Nutrition · IF 6.5

Serum-based biomarker development for dietary macronutrient densities and their association with breast and colorectal cancer risk in a cohort of postmenopausal females.

New evidencebiomarkerepidemiologybasic sciencediet therapy
Clinical takeawayConsider discussing dietary MUFA intake with postmenopausal females, particularly from dairy and meat products, as part of broader CRC risk reduction strategies, though causality is not established.
What it foundDietary MUFA density was associated with a 46% higher CRC risk (HR 1.46, 95% CI 1.10-1.93) in postmenopausal U.S. females.
ContextChallenges reliance on self-reported dietary data by using serum-based biomarkers, aligning with prior evidence linking MUFA intake to CRC risk.
Emergingsuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017

Decision at stakewhether dietary macronutrient composition influences colorectal cancer risk in postmenopausal women

Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.

U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗
Prentice RL … Zheng C · American Journal of Clinical Nutrition · IF 6.5 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues